Target intelligence / Profile preview

Kelch repeat and BTB domain-containing protein 4 (KBTBD4)

Target
KBTBD4
Molecular classification
E3 ubiquitin ligase substrate receptor, BTB-Kelch protein family, Cullin3-RING (CRL3) E3 ligase complex component
01

Overview

Kelch repeat and BTB domain-containing protein 4 (KBTBD4) is a substrate receptor component of the CULLIN3-RING E3 ubiquitin ligase complex, responsible for recruiting substrates for ubiquitination and subsequent proteasomal degradation. The protein contains an N-terminal BTB (Broad-Complex, Tramtrack, and Bric-à-brac) domain, a BACK (BTB and C-terminal Kelch) domain, and a C-terminal Kelch-repeat β-propeller domain critical for protein-protein interactions. In cancer, especially medulloblastoma, recurrent neomorphic mutations in KBTBD4's Kelch domain enable aberrant degradation of the transcriptional corepressor CoREST complex (RCOR1, LSD1/KDM1A, and HDAC1/2) by altering the substrate specificity of the E3 ligase, a process that can also be induced by the molecular glue UM171. These gain-of-function mutations are mechanistically linked to disease progression and represent both a therapeutic vulnerability and a molecular paradigm for drug-induced neosubstrate targeting by E3 ligase complexes.

Other names
BKLHD4FLJ10450HSPC252BTB and kelch domain-containing protein 4kelch repeat and BTB (POZ) domain-containing protein 4
02

Mechanism of action

UM171: Promotes neomorphic substrate recruitment to KBTBD4, mimicking cancer gain-of-function mutations, driving degradation of HDAC1/2-CoREST complexes. HDAC1/2 inhibitors: Block mutant KBTBD4 binding to its neosubstrate and inhibit proliferation of KBTBD4-mutant cancer cells

03

Biological functions

Substrate recognition for ubiquitin-mediated proteasomal degradationRegulation of turnover of transcriptional corepressor CoREST complex (RCOR1), KDM1A/LSD1, and HDAC2Protein-protein interaction modulation
04

Disease associations

Cancer (notably medulloblastoma)Potential role in other neoplastic disorders via aberrant protein degradation
05

Safety considerations

Potential off-target effects from drugs (e.g., HDAC1/2 inhibitors)General challenges in targeting E3 ligase substrate adaptors, including specificity and unintended substrate degradation
06

Interacting drugs

UM171 (a molecular glue degrader that phenocopies KBTBD4 neomorphic mutations)

1 more in the full profile.

07

Biomarkers

KBTBD4 mutation status (notably in medulloblastoma, hotspot indels or substitutions)Aberrant degradation of CoREST complex/HDAC1/2/KDM1A as functional readouts

Beyond the preview

Go deeper on Kelch repeat and BTB domain-containing protein 4 (KBTBD4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kelch repeat and BTB domain-containing protein 4 (KBTBD4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call